Anti-IL-6 therapy was initially developed for treating autoimmune diseases, but the role of IL-6 in chronic inflammation suggests that IL-6 blockade may be feasible for cancer treatment [22, 23]. The gene discussed is IL6; the disease is autoimmune disease.